{
    "nct_id": "NCT04975997",
    "official_title": "A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)",
    "inclusion_criteria": "Inclusion Criteria\n\n* Documented diagnosis of multiple myeloma (MM) and measurable disease.\n* Received 1 to 2 prior lines of anti-myeloma therapy.\n* Must have documented disease progression during or after their last anti-myeloma regimen.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.\n\nExclusion Criteria\n\n* Any condition that confounds the ability to interpret data from the study.\n* Has plasma cell leukemia, Waldenstrom's macroglobulinemia or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or clinically significant amyloidosis.\n* Known central nervous system involvement with MM.\n* Prior therapy with iberdomide.\n* Other protocol-defined Inclusion/Exclusion criteria apply.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}